"mouse Clone Model" for evaluating the immunogenicity and tumorigenicity of pluripotent stem cells

Stem Cell Research and Therapy

Volumn 6, Issue 1, 2015, Pages

  Zhang, Gang ^a,b,c   Zhang, Yi ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; AUTOIMMUNE DISEASE; AUTOTRANSPLANTATION; BIOLOGICAL MODEL; C57BL 6 MOUSE; CARCINOGENESIS; CARCINOGENICITY; CELL DIFFERENTIATION; CELL HETEROGENEITY; CLONING; EMBRYONIC STEM CELL; FIBROBLAST; GRAFT REJECTION; HEMATOPOIETIC CELL; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; MUSCLE CELL; NONHUMAN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; TETRAPLOIDY; ADVERSE EFFECTS; ANIMAL; ANIMAL MODEL; CYTOLOGY; GENETIC COMPLEMENTATION; IMMUNOLOGY; INDUCED PLURIPOTENT STEM CELL; NEOPLASMS, EXPERIMENTAL; TRANSPLANTATION;

ANIMALS; CELL DIFFERENTIATION; CLONING, ORGANISM; EMBRYONIC STEM CELLS; GENETIC COMPLEMENTATION TEST; INDUCED PLURIPOTENT STEM CELLS; MICE; MODELS, ANIMAL; MODELS, IMMUNOLOGICAL; NEOPLASMS, EXPERIMENTAL; REGENERATIVE MEDICINE; STEM CELL TRANSPLANTATION; TETRAPLOIDY;

EID: 84951102014     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-015-0262-3     Document Type: Article

References (29)

1. Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature. 2011;474:212-5.
2. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A. 1981;78:7634-8.
3. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-76.
4. Jincho Y, Araki R, Hoki Y, Tamura C, Nakamura M, Ando S, et al. Generation of genome integration-free induced pluripotent stem cells from fibroblasts of C57BL/6 mice without c-Myc transduction. J Biol Chem. 2010;285:26384-9.
5. Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T, et al. iPS cells produce viable mice through tetraploid complementation. Nature. 2009;461:86-90.
6. Kang L, Wang J, Zhang Y, Kou Z, Gao S. iPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell. 2009;5:135-8.
7. Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, Martin G, et al. Adult mice generated from induced pluripotent stem cells. Nature. 2009;461:91-4.
8. Wernig M, Lengner CJ, Hanna J, Lodato MA, Steine E, Foreman R, et al. A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. Nat Biotechnol. 2008;26:916-24.
9. Jia F, Wilson KD, Sun N, Gupta DM, Huang M, Li Z, et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods. 2010;7:197-9.
10. Polo JM, Liu S, Figueroa ME, Kulalert W, Eminli S, Tan KY, et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol. 2010;28:848-55.
11. Hanna J, Wernig M, Markoulaki S, Chiao-Wang Sun CW, Meissner A, Cassady JP, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science. 2007;318:1920-3.
12. Raya A, Rodríguez-Pizà I, Guenechea G, Vassena R, Navarro S, Barrero MJ, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature. 2009;460:53-9.
13. Wu G, Liu N, Rittelmeyer I, Sharma AD, Sgodda M, Zaehres H, et al. Generation of healthy mice from gene-corrected disease-specific induced pluripotent stem cells. PLoS Biol. 2011;9:e1001099.
14. Seetharam A, Tiriveedhi V, Mohanakumar T. Alloimmunity and autoimmunity in chronic rejection. Curr Opin Organ Transplant. 2010;15:531-6.
15. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KHS. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997;385:810-3.
16. Tam PPL, Rossant J. Mouse embryonic chimeras: tools for studying mammalian development. Development. 2003;22:6155-63.
17. Wakayama S, Kohda T, Obokata H, Tokoro M, Li C, Terashita Y, et al. Successful serial recloning in the mouse over multiple generations. Cell Stem Cell. 2013;12:293-7.
18. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-11.
19. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3:730-7.
20. Barabe F, Kenedy JA, Hope KJ, Dick JE. Modeling the initiation and progression of human acute leukemia in mice. Science. 2007;316:600-4.
21. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumor initiating cells. Nature. 2004;432:396-401.
22. Baker DE, Harrison NJ, Maltby E, Smith K, Moore HD, Shaw PJ, et al. Adaptation to culture of human embryonic stem cells and oncogenesis in vivo. Nat Biotechnol. 2007;25:207-15.
23. Maitra A, Arking DE, Shivapurkarv N, Ikeda M, Stastny V, Kassauei K, et al. Genomic alterations in cultural human embryonic stem cells. Nat Genet. 2005;37:1099-103.
24. Humpherys D, Eggan K, Akutsu H, Hochedlinger K, Rideout 3rd WM, Biniszkiewicz D, et al. Epigenetic instability in ES cells and cloned mice. Science. 2001;293:95-7.
25. Shih CC, Forman SJ, Chu P, Slovak M. Human embryonic stem cells are prone to generate primitive, undifferentiated tumors in engrafted human fetal tissues in severe combined immunodeficient mice. Stem Cells Dev. 2007;16:893-902.
26. Fujikawa T, Oh SH, Pi L, Hatch HM, Shupe T, Petersen BE. Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol. 2005;166:1781-91.
27. Knoepfler PS. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells. 2009;27:1050-6.
28. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature. 2007;448:313-7.
29. Belizário JE. Immunodeficient mouse models: an overview. Open Immunol J. 2009;2:79-85.